Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Carcinoma, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02611544
What this trial is testing

Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors

Who this might be right for
Breast NeoplasmsBreast CancerBreast Carcinoma+14 more
Indiana University 91
Not applicableStudy completedNCT05472064
What this trial is testing

Design of Chatbot Persona for Breast Cancer Screening Outreach Among Black Women

Who this might be right for
Breast Cancer
University of Washington 550
Post-approval studies (Phase 4)Study completedNCT02944604
What this trial is testing

The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy

Who this might be right for
Breastcancer
Peking University 240
Testing effectiveness (Phase 2)Ended earlyNCT02624700
What this trial is testing

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Virginia Commonwealth University 13
Large-scale testing (Phase 3)Active Not RecruitingNCT03701334
What this trial is testing

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 5,101
Testing effectiveness (Phase 2)Active Not RecruitingNCT03899792
What this trial is testing

Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Who this might be right for
Medullary Thyroid CancerInfantile MyofibromatosisInfantile Fibrosarcoma+2 more
Eli Lilly and Company 36
Testing effectiveness (Phase 2)Looking for participantsNCT06239194
What this trial is testing

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Who this might be right for
Biliary Tract CancerBreast CancerCervical Cancer+13 more
ModeX Therapeutics, An OPKO Health Company 285
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Testing effectiveness (Phase 2)Study completedNCT00191451
What this trial is testing

Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 150
Testing effectiveness (Phase 2)Looking for participantsNCT04836156
What this trial is testing

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Who this might be right for
HER2-negative Early Breast Cancer
Peking University People's Hospital 46
Not applicableUnknownNCT01779531
What this trial is testing

Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Guangdong Academy of Medical Sciences 640
Large-scale testing (Phase 3)Active Not RecruitingNCT05365178
What this trial is testing

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Breast Neoplasms
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 432
Large-scale testing (Phase 3)Active Not RecruitingNCT04915755
What this trial is testing

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 40
Not applicableStudy completedNCT00001898
What this trial is testing

Microarray Analysis for Human Genetic Disease

Who this might be right for
Breast NeoplasmHereditary Neoplastic SyndromeMelanoma+1 more
National Human Genome Research Institute (NHGRI) 1,500
Testing effectiveness (Phase 2)Ended earlyNCT04172597
What this trial is testing

Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Who this might be right for
Breast CancerColorectal CancerSolid Tumor+1 more
Spectrum Pharmaceuticals, Inc 1
Early research (Phase 1)Study completedNCT02060253
What this trial is testing

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
Memorial Sloan Kettering Cancer Center 9
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Testing effectiveness (Phase 2)Study completedNCT03310957
What this trial is testing

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Seagen Inc. 185
Testing effectiveness (Phase 2)Ended earlyNCT01131364
What this trial is testing

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Who this might be right for
Advanced Solid TumorBreast Cancer
Philogen S.p.A. 29
Not applicableStudy completedNCT04807595
What this trial is testing

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Who this might be right for
Breast Cancer
AstraZeneca 798
Next Page